Indications and Contraindications of Boston KPRO Types I and II

Boston Keratoprosthesis Type 1

“…These include patients with unilateral or bilateral corneal opacification with prior failed graft(s), limbal stem cell deficiency, severe neurotrophism, or corneal vascularization. 5,20 A recent review of the B-KPro by the American Academy of Ophthalmology further confirmed promising results in visual rehabilitation and safety profile across published series. 20 Increasing use of the B-KPro both in developed countries facing fresh tissue shortages and in developing countries with insufficient or absent eye banking infrastructure has led to a search for alternatives to fresh graft tissue carrier buttons.…”

“…3 The Boston Keratoprosthesis type 1 (B-KPro), approved by the Food and Drug Administration in 1992, has garnered widespread use over the past 2 decades, with more than 11 000 devices implanted in patients worldwide. 4,5 In selected cases, successful B-KPro implantation can be achieved using the patient's own trephined corneal tissue as a carrier graft; however, the majority of cases are performed using an allogeneic corneal button. The donor tissue in the B-KPro acts as a peripheral carrier and interface to facilitate suturing of the device to the host, rendering the otherwise highly desirable optical clarity of fresh tissue unnecessary.…”

Early Endophthalmitis Rates and Risk Factors After Corneal Transplant Surgeries in Medicare Beneficiaries From 2016 to 2019

“…12,13 Studies have also reported endophthalmitis rates after penetrating keratoplasty (PK), endothelial keratoplasty (EK), and keratoprosthesis. 2,[14][15][16][17][18][19] However, to the best of our knowledge, there have been no studies looking at the risk factors for developing endophthalmitis after multiple keratoplasty types from a nationally representative sample. Understanding the rates and risk factors of endophthalmitis postkeratoplasty could help guide patient counseling and play a role in developing prevention strategies.…”